Bio News
Merck failed to meet the primary endpoint in a phase 2 trial of tulisokibart, an anti-TL1A antibody it acquired for $10.8 billion (approximately 15 trillion won). Merck obtained the antibody through its 2023 acquisition of Prometheus Biosciences and began broad clinical development. Along with the successful phase 2b trial in hidradenitis suppurativa, Merck expects to complete the phase 2 rheumatoid arthritis trial next month and the phase 2 spondyloarthritis trial in June 2027.
BIOBOOK TEAM
biobookmedia@biobook.co.krRural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
HLB Submits FDA Resubmission for First-Line Liver Cancer Treatment
Celltrion Reports Third-Quarter Revenue of 1.5 Trillion Won and Operating Profit of 510 Billion Won, Up 69% Year Over Year
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
